Ulrik Lassen

Lassen Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class antibody therapeutics for the treatment of fibrosis, thyroid eye disease, and oncology. The company's lead program, LASN01, is a high-affinity monoclonal antibody that targets the interleukin-11 (IL-11) receptor, a key driver of fibro-inflammatory signaling in diseases like idiopathic pulmonary fibrosis and thyroid eye disease. Additionally, Lassen is advancing LASN500, a monoclonal antibody targeting the gp130 receptor to address various cancers and inflammatory conditions. Founded by industry veterans and supported by leading life science investors, the company leverages external discovery platforms to efficiently develop novel therapies for significant unmet medical needs.